Psychosis is a severe disorder of thought and perception where individuals are unable to distinguish reality from fantasy. Antipsychotics are used to treat all forms of psychosis including schizophrenia, dementia and psychosis secondary to Parkinson’s disease.
Psychosis is one of the most costly and debilitating mental disorders in the world, directly affecting approximately 4% of adults at some time in life. It is one of the largest of all drug markets: over $ 18 billion in yearly drug sales and growing. Unfortunately, the current antipsychotic drugs on the market can lead to obesity, diabetes, cardiovascular disease, sexual disfunction, seizures and sudden death.
Based on Dr. Seeman's over 40 years of ground breaking neuroscience research and drug development, Clera is developing a number of novel small-molecule drug candidates that have optimized “fast-off” affinity for D2 receptors and low affinity for other receptors, thereby reducing the risk of extrapyramidal signs, low blood pressure and cardiac effects. As a result, patients will have fewer side-effects and better outcomes.